CN104971102B - The pharmaceutical composition and its preparation method and application for treating diabetic nephropathy - Google Patents
The pharmaceutical composition and its preparation method and application for treating diabetic nephropathy Download PDFInfo
- Publication number
- CN104971102B CN104971102B CN201510151713.2A CN201510151713A CN104971102B CN 104971102 B CN104971102 B CN 104971102B CN 201510151713 A CN201510151713 A CN 201510151713A CN 104971102 B CN104971102 B CN 104971102B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- diabetic nephropathy
- fruit
- coptis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 52
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 45
- 244000247747 Coptis groenlandica Species 0.000 claims abstract description 45
- 239000009636 Huang Qi Substances 0.000 claims abstract description 45
- 210000000582 semen Anatomy 0.000 claims abstract description 44
- 239000000126 substance Substances 0.000 claims abstract description 42
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 27
- 244000268590 Euryale ferox Species 0.000 claims abstract description 27
- 241001278833 Rosa laevigata Species 0.000 claims abstract description 25
- 235000000661 Rosa laevigata Nutrition 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000002485 urinary effect Effects 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 229940100688 oral solution Drugs 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 8
- 210000002700 urine Anatomy 0.000 abstract description 5
- 102000009027 Albumins Human genes 0.000 abstract description 4
- 108010088751 Albumins Proteins 0.000 abstract description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract description 4
- 229940109239 creatinine Drugs 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 206010022530 Intercapillary glomerulosclerosis Diseases 0.000 abstract description 3
- 230000003111 delayed effect Effects 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 230000029142 excretion Effects 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000002131 composite material Substances 0.000 description 3
- 206010054805 Macroangiopathy Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 206010061989 glomerulosclerosis Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000009928 nephrosis Diseases 0.000 description 2
- 231100001027 nephrosis Toxicity 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 206010001580 Albuminuria Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to field of medicaments, and in particular to treat pharmaceutical composition of diabetic nephropathy and its preparation method and application.Technical problem solved by the invention is to provide the completely new pharmaceutical composition of one kind for treating diabetic nephropathy.Pharmaceutical composition of the present invention is with caulis sinomenii, semen astragali complanati, Radix Astragali, and the coptis is main bulk pharmaceutical chemicals, achievees the purpose that treat diabetic nephropathy, and pharmaceutical composition of the present invention can also add the fruit of Cherokee rose, and Gorgon fruit is further to promote the curative effect of pharmaceutical composition.The most typical symptom of diabetic nephropathy is nodular glomerulosclerosis, mainly with urinary albumin discharge rate how much for diagnosis index.Using after pharmaceutical composition of the present invention, albumen urinary output significantly reduces patient, and twenty-four-hour urine total protein levels, urinary albumin excretion ratio reduce, urinary albumin-creatinine ratio ratio reduces, serum creatinine level reduces, and patients ' life quality is obviously improved, and has delayed the progress of diabetic nephropathy disease.
Description
Technical field
The invention belongs to field of medicaments, and in particular to treat pharmaceutical composition of diabetic nephropathy and preparation method thereof and use
On the way.
Background technique
Diabetic nephropathy is one of Diabetic microvascular complication, is the important death cause of diabetic.Broad sense
Diabetes renal lesions include infection and vascular lesions.Infection has pyelonephritis and necrosis of renal papillae.Blood
Pipe venereal disease variation capilary and macroangiopathy, macroangiopathy include renal arteriosclerosis (involving trunk and branch) and kidney petty action
Arteries and veins hardens (involving people's ball and efferent glomerular arteriole).Microangiopathies refer to glomerulosclerosis, divide nodositas, exudative and diffusivity
Three kinds, three can individually combinable presence, in above-mentioned change, most typically nodular glomerulosclerosis.What we usually said
Diabetic nephropathy is glomerulosclerosis.Diabetic nephropathy there is no specific short.Treatment principle is：1. strict glycemic control to the greatest extent may be used
Blood glucose can be made close to normal level, prevent and delay that diabetic nephropathy occurs；2. delaying the rate of renal hypofunction；3. dialysis is controlled
Treatment and kidney transplant.
It is visible to using the document of traditional Chinese medical theory treatment diabetic nephropathy《Li Xiaojuan Experience in Treating diabetic nephropathy
Summary of experience》[Han Yunping, Liaoning medical pharmaceutical university, master thesis, 20090401]《Appoint flat Experience in Treating diabetic nephropathy warp
It tests》[mountain peak, Liaoning medical pharmaceutical university, master thesis, 20100401].
The present invention is intended to provide a kind of completely new, the clearly significant drug of curative effect for treating diabetic nephropathy.
Summary of the invention
Technical problem solved by the invention is to provide the completely new pharmaceutical composition of one kind for treating diabetic nephropathy.
Pharmaceutical composition of the present invention is with caulis sinomenii, semen astragali complanati, Radix Astragali, and the coptis is main bulk pharmaceutical chemicals, reaches treatment glycosuria
The purpose of sick nephrosis, pharmaceutical composition of the present invention can also add the fruit of Cherokee rose, and Gorgon fruit is further to promote the treatment of pharmaceutical composition
Effect.
1) pharmaceutical composition of the present invention is with caulis sinomenii, semen astragali complanati, Radix Astragali, when the coptis is bulk pharmaceutical chemicals：
Bulk pharmaceutical chemicals weight proportion is as follows：10-120 parts of caulis sinomenii, 10-120 parts of semen astragali complanati, 10-120 parts of Radix Astragali, coptis 5-
60 parts.
Bulk pharmaceutical chemicals preferred weight proportion is as follows：10-50 parts of caulis sinomenii, 10-50 parts of semen astragali complanati, 10-50 parts of Radix Astragali, coptis 5-
30 parts.
The further preferred weight proportion of bulk pharmaceutical chemicals is as follows：20-40 parts of caulis sinomenii, 20-40 parts of semen astragali complanati, 20-40 parts of Radix Astragali,
5-15 parts of the coptis.
Bulk pharmaceutical chemicals most preferably weight proportion is as follows：30 parts of caulis sinomenii, 30 parts of semen astragali complanati, 30 parts of Radix Astragali, 10 parts of the coptis.
2) pharmaceutical composition of the present invention is with caulis sinomenii, semen astragali complanati, Radix Astragali, the coptis, the fruit of Cherokee rose, when Gorgon fruit is bulk pharmaceutical chemicals：
Bulk pharmaceutical chemicals weight proportion is as follows：10-120 parts of caulis sinomenii, 10-120 parts of semen astragali complanati, 10-120 parts of Radix Astragali, coptis 5-
60 parts, 5-60 parts of the fruit of Cherokee rose, 5-60 parts of Gorgon fruit.
Bulk pharmaceutical chemicals preferred weight proportion is as follows：10-50 parts of caulis sinomenii, 10-50 parts of semen astragali complanati, 10-50 parts of Radix Astragali, coptis 5-
30 parts, 5-30 parts of the fruit of Cherokee rose, 5-30 parts of Gorgon fruit.
The further preferred weight proportion of bulk pharmaceutical chemicals is as follows：20-40 parts of caulis sinomenii, 20-40 parts of semen astragali complanati, 20-40 parts of Radix Astragali,
5-15 parts of the coptis, 10-20 parts of the fruit of Cherokee rose, 10-20 parts of Gorgon fruit.
Bulk pharmaceutical chemicals most preferably weight proportion is as follows：30 parts of caulis sinomenii, 30 parts of semen astragali complanati, 30 parts of Radix Astragali, 10 parts of the coptis, Jin Ying
15 parts, 15 parts of Gorgon fruit of son.
The most typical symptom of diabetic nephropathy is nodular glomerulosclerosis, how much is mainly to examine with urinary albumin discharge rate
Severed finger mark.Using after pharmaceutical composition of the present invention, albumen urinary output significantly reduces patient, twenty-four-hour urine total protein levels, urine
Albumin excretion rate reduces, and urinary albumin-creatinine ratio ratio reduces, and serum creatinine level reduces, and patients ' life quality is obviously improved, prolongs
The progress of diabetic nephropathy disease is delayed.
For the ease of application, conventionally or pharmaceutically acceptable auxiliary material can be added on the basis of bulk pharmaceutical chemicals
Common oral preparation is made.Such as powder, capsule, tablet, granule, capsule, oral solution.For answering for drug of the present invention
With feature, the preparation method of the pharmaceutical composition is additionally provided.
Such as：
Method one：Each bulk pharmaceutical chemicals are ground into fine powder, mixing powder；
Method two：Each bulk pharmaceutical chemicals are ground into fine powder, encapsulated capsule；
Method three：Each bulk pharmaceutical chemicals are ground into fine powder, tabletting tablet；
Method four：After the medicinal water boiling and extraction of each raw material, particle is made in concentrated extracting solution, granule；
Method five：After the medicinal water boiling and extraction of each raw material, concentrated extracting solution is made particle, encapsulated capsule；
Method six：After the medicinal water boiling and extraction of each raw material, concentrated extracting solution is made particle, tabletting tablet；
Method seven：After the medicinal water boiling and extraction of each raw material, oral solution is made.
The purpose for the treatment of diabetes may be implemented using the above method, but because of the simplicity of the convenience of application and preparation,
Inventor is made into granule use more.
To sum up, there is specific effect using medicine composite for curing diabetes provided by the invention, curative effect is stablized, nontoxic pair
Effect, controllably.
Specific embodiment
Illustrate below by way of specific description of embodiments of the present invention but does not limit the present invention.
The pharmaceutical composition that the present invention is used to treat diabetic nephropathy is made of the bulk pharmaceutical chemicals of following weight proportion：
1) pharmaceutical composition of the present invention is with caulis sinomenii, semen astragali complanati, Radix Astragali, when the coptis is bulk pharmaceutical chemicals：
Bulk pharmaceutical chemicals weight proportion is as follows：10-120 parts of caulis sinomenii, 10-120 parts of semen astragali complanati, 10-120 parts of Radix Astragali, coptis 5-
60 parts.
Bulk pharmaceutical chemicals preferred weight proportion is as follows：10-50 parts of caulis sinomenii, 10-50 parts of semen astragali complanati, 10-50 parts of Radix Astragali, coptis 5-
30 parts.
The further preferred weight proportion of bulk pharmaceutical chemicals is as follows：20-40 parts of caulis sinomenii, 20-40 parts of semen astragali complanati, 20-40 parts of Radix Astragali,
5-15 parts of the coptis.
Bulk pharmaceutical chemicals most preferably weight proportion is as follows：30 parts of caulis sinomenii, 30 parts of semen astragali complanati, 30 parts of Radix Astragali, 10 parts of the coptis.
2) pharmaceutical composition of the present invention is with caulis sinomenii, semen astragali complanati, Radix Astragali, the coptis, the fruit of Cherokee rose, when Gorgon fruit is bulk pharmaceutical chemicals：
Bulk pharmaceutical chemicals weight proportion is as follows：10-120 parts of caulis sinomenii, 10-120 parts of semen astragali complanati, 10-120 parts of Radix Astragali, coptis 5-
60 parts, 5-60 parts of the fruit of Cherokee rose, 5-60 parts of Gorgon fruit.
Bulk pharmaceutical chemicals preferred weight proportion is as follows：10-50 parts of caulis sinomenii, 10-50 parts of semen astragali complanati, 10-50 parts of Radix Astragali, coptis 5-
30 parts, 5-30 parts of the fruit of Cherokee rose, 5-30 parts of Gorgon fruit.
The further preferred weight proportion of bulk pharmaceutical chemicals is as follows：20-40 parts of caulis sinomenii, 20-40 parts of semen astragali complanati, 20-40 parts of Radix Astragali,
5-15 parts of the coptis, 10-20 parts of the fruit of Cherokee rose, 10-20 parts of Gorgon fruit.
Bulk pharmaceutical chemicals most preferably weight proportion is as follows：30 parts of caulis sinomenii, 30 parts of semen astragali complanati, 30 parts of Radix Astragali, 10 parts of the coptis, Jin Ying
15 parts, 15 parts of Gorgon fruit of son.
Inventor adjusts the dosage of bulk pharmaceutical chemicals in nearly clinical application in 2 years within the scope of following weight proportion, can be real
Now treat diabetic nephropathy purpose：
With caulis sinomenii, semen astragali complanati, Radix Astragali, when the coptis is bulk pharmaceutical chemicals, bulk pharmaceutical chemicals most preferably weight proportion is as follows：
30 parts of caulis sinomenii, 30 parts of semen astragali complanati, 30 parts of Radix Astragali, 10 parts of the coptis.
With caulis sinomenii, semen astragali complanati, Radix Astragali, the coptis, the fruit of Cherokee rose, when Gorgon fruit is bulk pharmaceutical chemicals, bulk pharmaceutical chemicals most preferably weight proportion
It is as follows：
30 parts of caulis sinomenii, 30 parts of semen astragali complanati, 30 parts of Radix Astragali, 10 parts of the coptis, 15 parts of the fruit of Cherokee rose, 15 parts of Gorgon fruit.
For the ease of application, on the basis of bulk pharmaceutical chemicals pharmaceutically acceptable auxiliary material can be added, common oral system is made
Agent.Such as powder, capsule, tablet, granule, capsule, oral solution.
The beneficial effect of pharmaceutical composition of the present invention is proved below by way of clinical statistics.
Inventor is applied to clinic using pharmaceutical composition of the present invention, takes different amounts proportion former for different indications
Material, is made following dosage form and is applied,
Prescription：When practical application, following weight proportion is can be used in bulk pharmaceutical chemicals：
1) 120 parts of caulis sinomenii, 10 parts of semen astragali complanati, 120 parts of Radix Astragali, 60 parts of the coptis.
2) 60 parts of caulis sinomenii, 120 parts of semen astragali complanati, 10 parts of Radix Astragali, 5 parts of the coptis.
3) 30 parts of caulis sinomenii, 10 parts of semen astragali complanati, 10 parts of Radix Astragali, 5 parts of the coptis.
4) 40 parts of caulis sinomenii, 50 parts of semen astragali complanati, 10 parts of Radix Astragali, 5 parts of the coptis.
5) 30 parts of caulis sinomenii, 20 parts of semen astragali complanati, 50 parts of Radix Astragali, 30 parts of the coptis.
6) 10 parts of caulis sinomenii, 40 parts of semen astragali complanati, 30 parts of Radix Astragali, 10 parts of the coptis.
7) 20 parts of caulis sinomenii, 120 parts of semen astragali complanati, 10 parts of Radix Astragali, 5 parts of the coptis, 5 parts of the fruit of Cherokee rose, 5 parts of Gorgon fruit.
8) 120 parts of caulis sinomenii, 10 parts of semen astragali complanati, 10 parts of Radix Astragali, 15 parts of the coptis, 10 parts of the fruit of Cherokee rose, 10 parts of Gorgon fruit.
9) 30 parts of caulis sinomenii, 10 parts of semen astragali complanati, 120 parts of Radix Astragali, 60 parts of the coptis, 60 parts of the fruit of Cherokee rose, 60 parts of Gorgon fruit.
10) 60 parts of caulis sinomenii, 10 parts of semen astragali complanati, 10 parts of Radix Astragali, 5 parts of the coptis, 5 parts of the fruit of Cherokee rose, 5 parts of Gorgon fruit.
11) 10 parts of caulis sinomenii, 40 parts of semen astragali complanati, 40 parts of Radix Astragali, 15 parts of the coptis, 20 parts of the fruit of Cherokee rose, 20 parts of Gorgon fruit.
12) 50 parts of caulis sinomenii, 10 parts of semen astragali complanati, 50 parts of Radix Astragali, 30 parts of the coptis, 30 parts of the fruit of Cherokee rose, 30 parts of Gorgon fruit
13) 30 parts of caulis sinomenii, 30 parts of semen astragali complanati, 30 parts of Radix Astragali, 10 parts of the coptis, 15 parts of the fruit of Cherokee rose, 15 parts of Gorgon fruit.
When clinical application, inventor is made into granule application, and above-mentioned different material medicine proportion relation system is respectively adopted
Standby granule, preparation method are as follows：After the medicinal water boiling and extraction of each raw material, particle is made in concentrated extracting solution, granule.
Pharmaceutical composition of the present invention：2 take daily dosage：Caulis sinomenii 30g, Radix Astragali 30g, coptis 10g, semen astragali complanati 30g, the fruit of Cherokee rose
15g, Gorgon fruit 15g；Three times a day.
Control drug：Take daily dosage：Radix Astragali 30g, coptis 10g, semen astragali complanati 30g, fruit of Cherokee rose 15g, Gorgon fruit 15g；One day three
It is secondary.
Inventor applies the 13rd group of medicine composite for curing diabetic nephropathy.In nearly 2 years more than 50 people for the treatment of, referring in China
Medicine and pharmacology meeting nephrosis branch 2006《Diabetic nephropathy diagnosis, differentiation of symptoms and signs for classification of syndrome and efficacy assessment standard》Grading therapeutic effect.This
About 2 weeks invention pharmaceutical composition onset times, healing time about 8 weeks, recurrence about 5%.
Non-clinical statistical data using pharmaceutical composition of the present invention and control drug is as follows：
Note：
Symptom disappears：Indicate that clinical symptoms disappear substantially, twenty-four-hour urine protein quantification<30mg/24h.
Symptom mitigates：Indicate that clinical symptoms are greatly reduced, 30mg/24h<Twenty-four-hour urine protein quantification<300mg/24h.
Total effective rate is disappeared by symptom and symptom mitigates in terms of sum.
Using medicine composite for curing Diabetic Nephropathy patients of the present invention, the albuminuria discharge capacity of patient is significantly reduced, thus
The process of diabetic nephropathy disease development can be slowed down.
To sum up, pharmaceutical composition of the present invention is observed through many years clinical statistics, finally determines caulis sinomenii, sand after screening prescription
Yuan Zi, the coptis, Radix Astragali be main bulk pharmaceutical chemicals, and add the fruit of Cherokee rose, Gorgon fruit further consolidates curative effect, treat diabetic nephropathy effect
Most preferably, a kind of completely new selection is provided for clinical treatment diabetes.
Claims (7)
1. the pharmaceutical composition for treating diabetic nephropathy, it is characterised in that：Bulk pharmaceutical chemicals weight proportion is as follows：
10-50 parts of caulis sinomenii, 10-50 parts of semen astragali complanati, 10-50 parts of Radix Astragali, 5-30 parts of the coptis, 5-30 parts of the fruit of Cherokee rose, Gorgon fruit 5-30
Part.
2. according to claim 1 for treating the pharmaceutical composition of diabetic nephropathy, it is characterised in that：Bulk pharmaceutical chemicals weight
Amount proportion is as follows：
20-40 parts of caulis sinomenii, 20-40 parts of semen astragali complanati, 20-40 parts of Radix Astragali, 5-15 parts of the coptis, 10-20 parts of the fruit of Cherokee rose, Gorgon fruit 10-
20 parts.
3. according to claim 2 for treating the pharmaceutical composition of diabetic nephropathy, it is characterised in that：Bulk pharmaceutical chemicals weight
Amount proportion is as follows：
30 parts of caulis sinomenii, 30 parts of semen astragali complanati, 30 parts of Radix Astragali, 10 parts of the coptis, 15 parts of the fruit of Cherokee rose, 15 parts of Gorgon fruit.
4. according to claim 1-3 for treating the pharmaceutical composition of diabetic nephropathy, it is characterised in that：Institute
Stating pharmaceutical composition is that oral preparation is conventionally made on the basis of bulk pharmaceutical chemicals；Or it is added pharmaceutically acceptable
Common oral preparation is made in auxiliary material.
5. according to claim 4 for treating the pharmaceutical composition of diabetic nephropathy, it is characterised in that：The oral system
Agent is powder, tablet, granule, capsule or oral solution.
6. claim 1-5 is described in any item for treating the preparation method of the pharmaceutical composition of diabetic nephropathy, feature
It is：
Method one：Each bulk pharmaceutical chemicals are ground into fine powder, mixing powder；Or
Method two：Each bulk pharmaceutical chemicals are ground into fine powder, encapsulated capsule；Or
Method three：Each bulk pharmaceutical chemicals are ground into fine powder, tabletting tablet；Or
Method four：After the medicinal water boiling and extraction of each raw material, particle is made in concentrated extracting solution, granule；Or
Method five：After the medicinal water boiling and extraction of each raw material, concentrated extracting solution is made particle, encapsulated capsule；Or
Method six：After the medicinal water boiling and extraction of each raw material, concentrated extracting solution is made particle, tabletting tablet；Or
Method seven：After the medicinal water boiling and extraction of each raw material, oral solution is made.
7. purposes of the described in any item pharmaceutical compositions of claim 1-5 in the drug that preparation reduces albumen urinary output.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510151713.2A CN104971102B (en) | 2014-04-03 | 2015-04-01 | The pharmaceutical composition and its preparation method and application for treating diabetic nephropathy |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410134086 | 2014-04-03 | ||
| CN2014101340867 | 2014-04-03 | ||
| CN201510151713.2A CN104971102B (en) | 2014-04-03 | 2015-04-01 | The pharmaceutical composition and its preparation method and application for treating diabetic nephropathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104971102A CN104971102A (en) | 2015-10-14 |
| CN104971102B true CN104971102B (en) | 2018-11-23 |
Family
ID=54268423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510151713.2A Expired - Fee Related CN104971102B (en) | 2014-04-03 | 2015-04-01 | The pharmaceutical composition and its preparation method and application for treating diabetic nephropathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104971102B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105194458B (en) * | 2015-10-21 | 2019-12-17 | 薛武 | Traditional Chinese medicine for treating diabetic nephropathy |
| CN105998854A (en) * | 2016-07-24 | 2016-10-12 | 刘咏梅 | Medicine for treating diabetic nephropathy and preparation method |
| CN108114032A (en) * | 2017-01-24 | 2018-06-05 | 青海春天药用资源科技利用有限公司 | There is the pharmaceutical composition of invigorating the blood |
| CN110772607A (en) * | 2019-10-21 | 2020-02-11 | 南方医科大学 | Traditional Chinese medicine composition for improving diabetic nephropathy and preparation thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228536A (en) * | 2011-06-09 | 2011-11-02 | 首都医科大学 | Chinese herbal extract for treating diabetic nephropathy and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7498048B2 (en) * | 2006-11-16 | 2009-03-03 | Jose Angel Olalde Rangel | Renal phyto-nutraceutical composition |
-
2015
- 2015-04-01 CN CN201510151713.2A patent/CN104971102B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228536A (en) * | 2011-06-09 | 2011-11-02 | 首都医科大学 | Chinese herbal extract for treating diabetic nephropathy and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 正清风痛宁治疗糖尿病肾病的疗效及对血浆内皮素水平的影响;罗来敏等;《江西医学院学报》;20091231;第49卷(第6期);第88-89页 * |
| 活血化瘀法治疗糖尿病肾病经验;张李兴等;《吉林中医药》;20081231;第28卷(第10期);第713-714页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104971102A (en) | 2015-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN104971102B (en) | The pharmaceutical composition and its preparation method and application for treating diabetic nephropathy | |
| CN103316219A (en) | Traditional Chinese medicinal preparation for treating phthisis and preparation method thereof | |
| CN105748543B (en) | A Chinese medicinal composition for treating rheumatic diseases, and its preparation method | |
| CN104645132A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy, preparation method, traditional Chinese medicine preparation and application of traditional Chinese medicine composition | |
| CN101011544A (en) | Gout rapid recovery pill(capsule) and preparation technique thereof | |
| CN103285206B (en) | Traditional Chinese medicinal liquor for treating rheumatic arthritis | |
| CN103520439A (en) | Traditional Chinese medicine for treating heat-toxicity accumulation type chronic osteomyelitis and preparation method thereof | |
| CN104706839A (en) | Traditional Chinese medicine preparation for treating rheumatic arthritis | |
| CN104971101B (en) | A kind of pharmaceutical composition for treating diabetic nephropathy and its preparation method and application | |
| CN103211961A (en) | Traditional Chinese medicine composition for treating chronic renal insufficiency | |
| CN104771640A (en) | Traditional Chinese medicine preparation for treating urethritis | |
| CN105412815B (en) | Traditional Chinese medicine composition for treating hyperthyroidism | |
| CN105125814B (en) | It is a kind of to treat chronic renal failure III, the Chinese medicine composition of IV phase | |
| CN109793826A (en) | A kind of Chinese medicine composition for treating fracture of children | |
| CN106620444A (en) | Pharmaceutical composition for treating eczema and preparation method thereof | |
| CN103285360B (en) | Traditional Chinese medicinal preparation for treating thromboangiitis obliterans, and preparation method thereof | |
| CN107213426A (en) | Treat Chinese patent drug of mammary gland disease and preparation method thereof | |
| CN107260866A (en) | It is a kind of to treat Chinese medicine preparation of hemorrhoid and preparation method thereof | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN106880683A (en) | External-applied ointment for treating hemorrhoid | |
| CN106511946A (en) | Traditional Chinese medicine for treating chronic glomerulonephritis and preparation method thereof | |
| CN105998449A (en) | Traditional Chinese medicine preparation for treating phlebitis and preparation method thereof | |
| CN104491726A (en) | Traditional Chinese medicine composition for treating prostatic hyperplasia and preparation method of traditional Chinese medicine composition | |
| CN105311269A (en) | Traditional Chinese medicine preparation capable of reducing blood sugar and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181123 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |